Buffalo, United States
For-Robin, Inc., founded in 2012 by Dr. Kate Rittenhouse-Olson, is a biotechnology pioneer in the field of antibody immunotherapy. Headquartered in the United States, the company stands at the forefront of cancer treatment innovation. Named in honor of the founder’s sister who succumbed to breast cancer, For-Robin, Inc. is intensely committed to developing therapies for breast cancer, with a particular focus on subtypes such as triple negative breast cancer which currently lack targeted solutions.
The company’s flagship technology, the monoclonal antibody JAA-F11 and its humanized counterparts, exhibit potential applicability beyond breast cancer, targeting colon, prostate, and bladder carcinoma as well. This promising proprietary technology positions For-Robin, Inc. as a versatile player in oncology.
The company received its last investment of $2.00M in the form of a grant on 04 May 2015. Despite the absence of recent investments, their distinctive focus presents a unique opportunity for investors interested in breakthrough cancer therapies.
